Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, insulin degludec/insulin aspart (Ryzodeg®) cannot be endorsed for use within NHS Wales for the treatment of diabetes mellitus in adults, adolescents and children from the age of 2 years. |
||
|
||
Medicine details |
||
| Medicine name | insulin degludec/insulin aspart (Ryzodeg®) | |
| Formulation | 100 units/ml solution for injection | |
| Reference number | 838 | |
| Indication | Treatment of diabetes mellitus in adults, adolescents and children from the age of 2 years |
|
| Company | Novo Nordisk Ltd | |
| BNF chapter | Endocrine system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 29/07/2013 | |